Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tibet AIM Pharm. Inc. specializes in the development and manufacturing of generic and specialty pharmaceuticals, primarily targeting the Chinese market. The company benefits from a high gross margin of 82.1% and a debt-free balance sheet, allowing for operational flexibility and resilience in a competitive landscape.
Tibet AIM Pharm generates revenue through the sale of generic and specialty drugs, leveraging its strong R&D capabilities to develop cost-effective alternatives to branded medications. The company's competitive advantages include a robust pipeline of products, established relationships with healthcare providers, and a focus on high-margin therapeutic areas.
Regulatory approvals for new generic drugs
Changes in healthcare policies impacting drug pricing
Market share shifts in the Chinese pharmaceutical sector
Fluctuations in raw material costs affecting margins
Regulatory changes impacting drug approval processes
Technological disruption in drug manufacturing processes
Increased competition from other generic manufacturers
Potential price erosion due to market saturation
Limited cash reserves for R&D investment
Dependence on a few key products for revenue
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but overall healthcare spending can be affected by GDP growth and consumer spending patterns.
Minimal impact as the company operates with no debt, but rising rates could indirectly affect consumer spending on healthcare products.
minimal
value - The company’s strong margins and debt-free balance sheet appeal to value investors looking for stability.
low - Historically stable performance with low beta relative to the broader market.